Lupus Anticoagulant Evaluation

Lupus anticoagulant is one of the most misnamed tests in medicine. Despite its name, it does not cause bleeding, and most people who have it do not have lupus. What it actually does is push your blood toward clotting, raising your risk of stroke, deep vein blood clots, lung clots, and recurrent miscarriage.

Detecting it reliably is harder than it sounds. A single clotting test misses a meaningful fraction of cases, so this panel runs two different assays that catch the antibody from different angles, plus an interpretive workup that distinguishes a true antibody from other reasons your blood might clot slowly in a tube.

What This Panel Reveals

Lupus anticoagulant is part of a family of antibodies called antiphospholipid antibodies. They attach to fats on the surface of blood cells and clotting proteins, and they shift the entire clotting system toward forming clots inside arteries and veins. People who carry these antibodies persistently can develop antiphospholipid syndrome, a condition that has been linked to a meaningful share of strokes in younger adults and to a notable fraction of recurrent pregnancy losses.

The panel is built around a quirk of laboratory chemistry. Lupus anticoagulant antibodies bind to the phospholipids (the fatty molecules) that clotting tests rely on, which makes blood clot more slowly in a test tube even though the same antibody speeds up clotting inside the body. Two different clotting reactions are run to catch this slowing, because no single assay finds every case. The dilute Russell viper venom time (dRVVT) uses snake venom to trigger one part of the clotting cascade, and the lupus-sensitive partial thromboplastin time (PTT-LA) triggers a different part. The third component is the interpretive workup, which uses mixing and confirmation steps to prove that a slowed clotting time is actually caused by an antibody rather than a clotting factor deficiency or a medication.

Running both assays matters because the antibodies are heterogeneous. International guidelines from the International Society on Thrombosis and Haemostasis (ISTH) specifically recommend using two phospholipid-dependent assays based on different coagulation pathways for this reason. Skipping one of them means missing real cases.

How to Read Your Results Together

The panel produces a final interpretation of positive, negative, or indeterminate, but the individual results tell you more than the bottom line.

What to Do with Your Results

A single positive result does not diagnose antiphospholipid syndrome. The condition is defined by the antibody being present on two separate occasions at least 12 weeks apart. Transient positivity is common after viral illness, certain medications, and inflammation, and it usually resolves on its own. Confirming persistence is the entire point of retesting.

If your panel comes back positive, the next step is to add the two solid-phase antibody tests that complete the antiphospholipid workup: anticardiolipin antibodies and anti-beta-2-glycoprotein I antibodies, both IgG and IgM. Patients who test positive on all three antibody categories, known as triple positive, face the highest clot risk. Cohort studies consistently show triple positive patients have the highest rates of thrombosis recurrence over long-term follow-up.

Treatment decisions depend on whether you have already had a clot or pregnancy loss. The TRAPS randomized trial in triple positive patients found that rivaroxaban, a direct oral anticoagulant, was inferior to warfarin, with the combined rate of thrombosis, major bleeding, and vascular death occurring in 19 percent of the rivaroxaban arm versus 3 percent of the warfarin arm. If you receive a positive panel, share it with a hematologist before any treatment decision.

When Results Can Be Misleading

Anticoagulant medications are the largest source of false results across the entire panel. Direct oral anticoagulants like rivaroxaban, apixaban, and dabigatran interfere with both the dRVVT and PTT-LA reactions and can cause false positives. Heparin can do the same unless the lab neutralizes it. Warfarin can cause both false positives and false negatives. The cleanest read comes from blood drawn before anticoagulation starts, or after a supervised washout period.

Active inflammation, recent infection, and very high levels of clotting factor VIII can also distort the assays. If you are sick when you draw the panel, repeat it once you have recovered.